The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial.
 
Nicolas Penel
Consulting or Advisory Role - PharmaMar
Research Funding - Bayer (Inst); PharmaMar (Inst); Roche/Genentech (Inst)
 
Olivier Mir
No Relationships to Disclose
 
Antoine Italiano
No Relationships to Disclose
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst)
 
Jennifer Wallet
No Relationships to Disclose
 
Francois Bertucci
No Relationships to Disclose
 
Christine Chevreau
No Relationships to Disclose
 
Sophie Piperno-Neumann
No Relationships to Disclose
 
Emmanuelle Bompas
No Relationships to Disclose
 
Sebastien Salas
No Relationships to Disclose
 
Christophe Perrin
No Relationships to Disclose
 
Corinne Delcambre
No Relationships to Disclose
 
Bernadette Lieg-Atzwanger
No Relationships to Disclose
 
Maud Toulmonde
No Relationships to Disclose
 
Thomas Ryckewaert
No Relationships to Disclose
 
Isabelle Laure Ray-Coquard
No Relationships to Disclose
 
Stephanie Clisant Delaine
No Relationships to Disclose
 
Axel Le Cesne
No Relationships to Disclose
 
Thomas Brodowicz
Research Funding - Bayer (Inst)